منابع مشابه
Targeting the PD-1/PD-L1 axis in the treatment of lung cancer
Lung cancer is the leading cause of cancer-related deaths in men and women [1]. Almost 80% of bronchogenic carcinomas are of the non-small cell lung cancer (NSCLC) subtype and approximately half of the patients with newly diagnosed NSCLC present with metastatic disease. The median overall survival (OS) for these patients is approximately 10 months and the 5-year survival rates are less than 1% ...
متن کاملTargeting PD-1/PD-L1 in lung cancer: current perspectives
Increased understanding of tumor immunology has led to the development of effective immunotherapy treatments. One of the most important advances in this field has been due to pharmacological design of antibodies against immune checkpoint inhibitors. Anti-PD-1/PD-L1 antibodies are currently in advanced phases of clinical development for several tumors, including lung cancer. Results from Phase I...
متن کاملTowards targeting PD-1/PD-L1 axis in breast cancer, pre-clinical data
PD-L1 is a ligand that upon binding to its receptor (PD-1) on T-cells leads to T-cell anergy/and or apoptosis [1,2]. We have shown that PD-L1 is expressed in breast cancer where its expression correlates with estrogen receptor (ER) negativity [3]. To understand the mechanism of the constitutive expression of PD-L1 in tumor cells of ER negative cells we used gene-in and out approach, large scale...
متن کاملPD-1/PD-L1 blockades in non-small-cell lung cancer therapy
Lung cancer is the leading cause of cancer death in males and the second leading cause of death in females worldwide. Non-small-cell lung cancer (NSCLC) is the main pathological type of lung cancer, and most newly diagnosed NSCLC patients cannot undergo surgery because the disease is already locally advanced or metastatic. Despite chemoradiotherapy and targeted therapy improving clinical outcom...
متن کاملOngoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
Compared to chemotherapy, promising results have been obtained by blocking the PD-1 pathway using antibodies that inhibit programmed cell death protein 1 (PD-1) or programmed cell death protein ligand 1 (PD-L1). Furthermore, global researchers and doctors are exploring how to optimize this immunotherapy in 270 clinical studies. However, Chinese clinical trials of these agents remain in the earl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Cancer Journal
سال: 2018
ISSN: 1540-336X,1528-9117
DOI: 10.1097/ppo.0000000000000300